ACRO Biomedical Co Ltd
Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products in Indiana and internationally. It is involved in the development and sale of cordyceps related products, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. wa… Read more
ACRO Biomedical Co Ltd (ACBM) - Total Assets
Latest total assets as of September 2025: $4.32K USD
Based on the latest financial reports, ACRO Biomedical Co Ltd (ACBM) holds total assets worth $4.32K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ACRO Biomedical Co Ltd - Total Assets Trend (2015–2025)
This chart illustrates how ACRO Biomedical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ACRO Biomedical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
ACRO Biomedical Co Ltd's total assets of $4.32K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how ACRO Biomedical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ACRO Biomedical Co Ltd's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 29.1% of total assets in 2025, down from 92.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
ACRO Biomedical Co Ltd Competitors by Total Assets
Key competitors of ACRO Biomedical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $281.56 Million |
|
Azure Holding Group Corp
PINK:AZRH
|
USA | $16.92 Million |
|
Constellation Capital Corp.
V:CNST-P
|
Canada | CA$627.53K |
|
Little Fish Acquisition I Corp.
V:LILL-P
|
Canada | CA$56.48K |
|
Hana 30 Special Purpose Acquisition Company
KQ:469880
|
Korea | ₩17.89 Billion |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
ACRO Biomedical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ACRO Biomedical Co Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ACRO Biomedical Co Ltd is currently not profitable relative to its asset base.
ACRO Biomedical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.00 | 3.98 |
| Quick Ratio | 0.01 | 0.00 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-432.62K | $ -316.60K | $ 714.27K |
ACRO Biomedical Co Ltd - Advanced Valuation Insights
This section examines the relationship between ACRO Biomedical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.12 |
| Latest Market Cap to Assets Ratio | 2.13 |
| Asset Growth Rate (YoY) | -55.9% |
| Total Assets | $14.10K |
| Market Capitalization | $30.04K USD |
Valuation Analysis
Premium Asset Valuation: The market values ACRO Biomedical Co Ltd's assets at a significant premium ( 2.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: ACRO Biomedical Co Ltd's assets decreased by 55.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ACRO Biomedical Co Ltd (2015–2025)
The table below shows the annual total assets of ACRO Biomedical Co Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $14.10K | -55.91% |
| 2024-12-31 | $31.97K | -95.35% |
| 2023-12-31 | $687.49K | 0.00% |
| 2022-12-31 | $687.49K | -9.67% |
| 2021-12-31 | $761.08K | -23.74% |
| 2020-12-31 | $998.05K | +7.07% |
| 2019-12-31 | $932.13K | -37.14% |
| 2018-12-31 | $1.48 Million | +170.44% |
| 2017-12-31 | $548.31K | +21546.66% |
| 2016-12-31 | $2.53K | -91.40% |
| 2015-12-31 | $29.46K | -- |